CORD-19:c738a511a9c18e7e831b40f1ec3605fe4cdeb6d1 / 11326-11844 JSONTXT

{"project":"CORD-19-Sentences","denotations":[{"id":"TextSentencer_T67","span":{"begin":0,"end":518},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Unfortunately, hypofractionated nodal irradiation has yet to see widespread adoption in the United States, although a nascent literature does suggest it is safe to employ 40 Gy in 15 daily fractions targeting the breast/chest wall and regional nodes (presuming the supraclavicular hotspot is below 105%; otherwise 39Gy in 15 fractions is preferred) 33, [41] [42] [43] , with ongoing studies utilizing this regimen in a randomized fashion to suggest true clinical equipoise (RT-CHARM: NCT03414970; FABREC: NCT03422103)."}

{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T67","span":{"begin":0,"end":518},"obj":"Sentence"}],"text":"Unfortunately, hypofractionated nodal irradiation has yet to see widespread adoption in the United States, although a nascent literature does suggest it is safe to employ 40 Gy in 15 daily fractions targeting the breast/chest wall and regional nodes (presuming the supraclavicular hotspot is below 105%; otherwise 39Gy in 15 fractions is preferred) 33, [41] [42] [43] , with ongoing studies utilizing this regimen in a randomized fashion to suggest true clinical equipoise (RT-CHARM: NCT03414970; FABREC: NCT03422103)."}

{"project":"CORD-19-PD-UBERON","denotations":[{"id":"T37","span":{"begin":213,"end":219},"obj":"Body_part"},{"id":"T38","span":{"begin":220,"end":230},"obj":"Body_part"},{"id":"T39","span":{"begin":220,"end":225},"obj":"Body_part"}],"attributes":[{"id":"A37","pred":"uberon_id","subj":"T37","obj":"http://purl.obolibrary.org/obo/UBERON_0000310"},{"id":"A38","pred":"uberon_id","subj":"T38","obj":"http://purl.obolibrary.org/obo/UBERON_0016435"},{"id":"A39","pred":"uberon_id","subj":"T39","obj":"http://purl.obolibrary.org/obo/UBERON_0001443"}],"text":"Unfortunately, hypofractionated nodal irradiation has yet to see widespread adoption in the United States, although a nascent literature does suggest it is safe to employ 40 Gy in 15 daily fractions targeting the breast/chest wall and regional nodes (presuming the supraclavicular hotspot is below 105%; otherwise 39Gy in 15 fractions is preferred) 33, [41] [42] [43] , with ongoing studies utilizing this regimen in a randomized fashion to suggest true clinical equipoise (RT-CHARM: NCT03414970; FABREC: NCT03422103)."}